Evidence map›Paper›PMID 34840484›Full record

ArticleJournal of clinical and experimental hepatology

The Outcome in Cirrhosis after Hospital Discharge is Not Worsened with COVID-19 Infection: A Propensity Score-matched Analysis.

Manas Vaishnav, Anshuman Elhence, Sagnik Biswas, Piysuh Pathak, Abhinav Anand, Sabreena Sheikh, Vishwajeet Singh, Souvik Maitra, Amit Goel, Shalimar

Open access · bronzeAbstract read
In one paragraph

Article in Journal of clinical and experimental hepatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Manas VaishnavDepartment of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India.
Anshuman ElhenceDepartment of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India.
Sagnik BiswasDepartment of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India.
Piysuh PathakDepartment of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India.
Abhinav AnandDepartment of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India.
Sabreena SheikhDepartment of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India.
Vishwajeet SinghDepartment of Biostatistics, All India Institute of Medical Sciences, New Delhi, India.
Souvik MaitraDepartment of Anaesthesiology, Pain Medicine & Critical Care, All India Institute of Medical Sciences, New Delhi, India.
Amit GoelDepartment of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.
ShalimarDepartment of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India.
All India Institute of Medical Sciences · INSanjay Gandhi Post Graduate Institute of Medical Sciences · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Patients with cirrhosis and coronavirus disease-2019 (COVID-19) have high in-hospital mortality. The information on the outcome of cirrhosis patients in the posthospitalization period is limited. Aims: We aimed to study the outcome of cirrhosis patients with COVID-19 after hospital discharge. Methods: The records of the cirrhosis patients discharged after COVID-19 were reviewed. Their data were compared with a similar number of cirrhosis patients without COVID-19 after propensity score matching for age, sex, etiology of cirrhosis, and model for end-stage liver disease (MELD) score. Results: Cirrhosis patients with (n = 92) or without (n = 92) COVID-19 were included in 1:1 ratio. The mortality among COVID-19 (22; 23.9%) and non-COVID-19 (19; 20.7%) were comparable (HR 1.224; 95% CI 0.663-2.263, Conclusion: Short-term outcomes of patients with cirrhosis who survive the initial insult of COVID-19 are not different from patients without COVID-19, and survival is determined by the severity of liver disease at discharge.

Indexed as

ACE2, Angiotensin-converting enzyme 2AD, acute decompensationAIH, autoimmune hepatitisAlk P, alkaline phosphataseALT, alanine aminotransferaseAST, aspartate aminotransferasechronic liver diseasecoronavirusCOVID-19, coronavirus disease-2019CTP, Child-Turcotte-PughGI, GastrointestinalHBV, hepatitis B virusHCV, hepatitis C virusINR, international normalized ratioIQR, interquartile rangeMELD, model for end-stage liver diseasemortalityNAFLD, nonalcoholic fatty liver diseasepandemicTLC, Total leukocyte countvirus

Identifiers

PMID34840484
PMCPMC8610830
OpenAlexW3216106388

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.